Sotrovimab might just be the answer to all our troubles as it will help lessen the number of coronavirus cases in the hospital which faces immense pressure. Here’s how Sotrovimab can lessen the impact of the virus.
Sotrovimab Mitigates The Virus Impact
So, while the focus has entirely been centered on vaccinations, those that have been infected have been neglected with regard to treatment methods. In the midst of the Omicron variant spreading, a look at treatment options through Sotrovimab have been examined.
For those infected with Covid-19 at present or in the future will be able to have a treatment option to mitigate the impact of the virus on the body as well as the impact on health facilities. But, the treatment needs to be taken within five days of infection which is where the concerns lie.
Slow Covid-19 Testing
With the testing capacity being very slow due to the lack of PCR or rapid antigen tests, many patients infected with the virus might miss their window to get the treatment as results are not readily available in order to take action.
At the same time, the lack of knowledge within the community about the virus and its treatment options is of big concern. This will in effect increase the rate of infection and lead to severe cases not being avoided. This is where Sotrovimab comes in.
According to the Guardian, many vulnerable patients will miss out on the treatment of the virus due to slow tests for the virus.
Omicron Peak To Be Reached In Coming Weeks
As the coronavirus pandemic has been around for over two years now, looking at ways to lessen infections is the greatest priority. However, with the Omicron Variant being less severe on the body and the peak of the virus expected to be reached within the coming weeks, Australians are set to reach the end of the virus’ severe impact.
While this may be good news, considering treatment options shouldn’t be looked past as every solution can make the pandemic better. At this time, people with underlying conditions such as diabetes, heart or lung disease as well as cancer will benefit immensely from Sotrovimab.